Science Explorer Back to mapMap

Amyloidosis: Diagnosis, Treatment, Outcomes

Amyloidosis: Diagnosis, Treatment, Outcomes is a research topic within Molecular Biology. Science Explorer counts 22k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the molecular mechanisms, diagnosis, treatment, and prognosis of amyloidosis, with a particular emphasis on transthyretin-related cardiac and familial amyloid polyneuropathy. It covers topics such as RNAi therapy, cardiovascular magnetic resonance, and immunoglobulin light chain involvement.

  • Transthyretin
  • Cardiac Amyloidosis
  • Light Chain Amyloidosis
  • RNAi Therapy
  • Diagnosis
  • Treatment
  • Prognosis
  • Familial Amyloid Polyneuropathy
  • Immunoglobulin Light Chain
  • Cardiovascular Magnetic Resonance
Research works
22k
fractional, since 1950
In the world top 10%
2.2k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+28%
the tick is no change
Largest producer
United States
42% of the 10 largest, 2022-now
Amyloidosis: Diagnosis, Treatment, Outcomes

Which countries lead Amyloidosis: Diagnosis, Treatment, Outcomes research?

By volume, the United States and China publish the most (1.6k and 456 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.6k works
  2. 2 China 456 works
  3. 3 Japan 396 works
  4. 4 Italy 329 works
  5. 5 India 227 works
  6. 6 France 206 works
  7. 7 Spain 186 works
  8. 8 United Kingdom 182 works
  9. 9 Germany 163 works
  10. 10 Brazil 114 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 41.9%China: 11.7%Japan: 10.2%Italy: 8.5%6 others listed: 27.7%42%largest
United States1,628 · 41.9%China456 · 11.7%Japan396 · 10.2%Italy329 · 8.5%6 others listed1,077 · 27.7%

Shares of the rows listed above, not of the whole node.

Which institutions lead Amyloidosis: Diagnosis, Treatment, Outcomes research?

By volume in 2022-now, Mayo Clinic publishes the most Amyloidosis: Diagnosis, Treatment, Outcomes research, followed by Harvard University and University College London.

Who are the leading researchers in Amyloidosis: Diagnosis, Treatment, Outcomes?

The most-cited researchers publishing on Amyloidosis: Diagnosis, Treatment, Outcomes include John J.V. McMurray, Stephan Windecker and Giuseppe Remuzzi.

  1. 1 John J.V. McMurray United Kingdom 349k citations
  2. 2 Stephan Windecker Switzerland 338k citations
  3. 3 Giuseppe Remuzzi Italy 328k citations
  4. 4 Graeme J. Hankey Australia 316k citations
  5. 5 Gregory Y.H. Lip United Kingdom 311k citations
  6. 6 John Q. Trojanowski United States 286k citations
  7. 7 Hagop M. Kantarjian United States 273k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Amyloidosis: Diagnosis, Treatment, Outcomes?

The most cited paper in Amyloidosis: Diagnosis, Treatment, Outcomes is "Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy" (Maj-Linda B. Selenica, Milene Lara Brownlow, Jeffy P. Jimenez et al., 2012), with 10,400 citations. Next come "Protein Misfolding, Functional Amyloid, and Human Disease" (6,490) and "Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein" (5,424).

Most cited papers
#PaperReleasedCitations
1 Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy Maj-Linda B. Selenica, Milene Lara Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases Open access 10 Jul 2012 10,400
2 Protein Misfolding, Functional Amyloid, and Human Disease Fabrizio Chiti, Christopher Martin Dobson · Annual Review of Biochemistry Review 7 Apr 2006 6,490
3 Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein George G. Glenner, Caine W. Wong · Biochemical and Biophysical Research Communications May 1984 5,424
4 Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease Alison Goate et al. · Nature 21 Feb 1991 4,701
5 Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis Rakez Kayed, Elizabeth Head, Jennifer L. Thompson et al. · Science 17 Apr 2003 4,103
All 100 most cited papers, with filters and sorting

Where is Amyloidosis: Diagnosis, Treatment, Outcomes research done?

The largest centres of Amyloidosis: Diagnosis, Treatment, Outcomes research in 2022-now are New York (United States), Beijing (China), London (United Kingdom) and Boston (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Clarkston, Kumamoto and Rochester.

Largest cities, 2022-now

  1. 1 New YorkUnited States 107 works
  2. 2 BeijingChina 105 works
  3. 3 LondonUnited Kingdom 97 works
  4. 4 BostonUnited States 94 works
  5. 5 TokyoJapan 86 works
  6. 6 ParisFrance 72 works
  7. 7 ClevelandUnited States 60 works
  8. 8 RomeItaly 50 works
  9. 9 MadridSpain 50 works
  10. 10 PhiladelphiaUnited States 47 works

Where it is the local speciality

  1. ClarkstonUS · 24.6 works1058×
  2. KumamotoJP · 33.6 works31×
  3. RochesterUS · 41.1 works20×
  4. ScottsdaleUS · 37.0 works15×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Amyloidosis: Diagnosis, Treatment, Outcomes than the world average.

See Amyloidosis: Diagnosis, Treatment, Outcomes on the map

Where is the best place to study Amyloidosis: Diagnosis, Treatment, Outcomes?

Among universities, judged by research, University College London, Columbia University and Harvard University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 20.97%fractional works in this field (log) →share of work in the world top 10% →University College L…Scuola Superiore San…Columbia UniversityHarvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1University College LondonUnited Kingdom 92.925.1%7.7×55 +43.3%
2Columbia UniversityUnited States 83.519.8%9.2×45 +29.8%
3Harvard UniversityUnited States 83.217.5%4.2×60 +24.4%
4Scuola Superiore Sant'AnnaItaly 65.021.2%31.8×13 +231.1%
5University of Tennessee at KnoxvilleUnited States 63.326.6%6.8×12 +62.9%
6Medical University of ViennaAustria 61.015.3%16.6×24 +45.7%
7Cornell UniversityUnited States 60.521.1%3.0×17 +28.6%
8Heidelberg UniversityGermany 60.319.8%5.8×20 -8.0%
9Kumamoto UniversityJapan 59.916.6%45.3×30 +25.2%
10University of PaduaItaly 59.026.7%3.3×12 +155.8%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Amyloidosis: Diagnosis, Treatment, Outcomes, country by country

Is Amyloidosis: Diagnosis, Treatment, Outcomes research growing?

Output in 2022-2025 was 28% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Amyloidosis: Diagnosis, Treatment, Outcomes.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Amyloidosis: Diagnosis, Treatment, Outcomes as a percentage of every work published that year, 0.021% in 2024.

still counting0.020%0.040%Amyloidosis: Diagnosis, Treatment, Outcomes0.022% in 202519801990200020102020

Fractional works of Amyloidosis: Diagnosis, Treatment, Outcomes over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Amyloidosis: Diagnosis, Treatment, Outcomes10.1% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Amyloidosis: Diagnosis, Treatment, Outcomes. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.